SquamousCellCarcinomaofSkin near Saint Petersburg, FL

Care Philosophy: Dr Chung's laboratory was among the first to recognize the importance of human papillomavirus (HPV) in the etiology of certain HNC as seen in one of the four subtypes in our molecular characterization study. Specifically the research showed that the most significantly deregulated genes in the HPV-positive tumors are cell cycle regulators. These data provided evidence that HPV-positive tumors may be more sensitive to chemotherapy and molecular inhibitors that specifically target cell cycle. In addition, her research findings contributed to establish the prognostic implication of the HPV status. Patients with HPV-positive HNC have a better prognosis compared to patients with HPV-negative HNC.

Care Philosophy: Dr Andrew (Andy) Brohl is a medical oncologist and physician-scientist. His clinical interest is in the care of patients with a diagnosis of sarcoma or a cutaneous (skin) malignancy, including melanoma. Dr Brohl's laboratory research focuses on the utilization of genomics and other high-throughput technologies to learn more about rare cancers and for clinically translational applications. Examples of his current projects include genomic analysis of rare cancer subtypes, identification of drug targets from -omics datatypes, application of genomics for personalized cancer therapy, and development of non-invasive molecular profiling technology.

Care Philosophy: Each and every patient should be evaluated and treated personally by the physician. Every effort possible made to run on time and limit wait times.

Care Philosophy: Dr Khushalani is the Vice Chair for the Department of Cutaneous Oncology at Moffitt Cancer Center. Dr Khushalani's clinical interest is the development of novel therapeutics for people diagnosed with melanoma and other skin cancers. He is greatly interested in the treatment of uveal melanoma, and melanoma that has metastasized to the brain. Dr Khushalani is interested in research on angiogenesis in melanoma and the translation of findings into clinical therapeutics.He is studying the economic impact of new melanoma drugs on healthcare (pharmacoeconomics) with an aim to devise strategies to reduce cost.Dr Khushalani earned his MD from Topiwala National Medical College, University of Bombay, in Maharashtra, India.